

# THE LANCET

## Rheumatology

### Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Schmiedeberg K, Vuilleumier N, Pagano S, et al. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. *Lancet Rheumatol* 2021; published online Oct 26. [https://doi.org/10.1016/S2665-9913\(21\)00328-3](https://doi.org/10.1016/S2665-9913(21)00328-3).

Table 1. Baseline characteristics of RA patients eligible for a third anti-SARS-CoV-2 mRNA based vaccine dose

	RA Patients receiving three vaccine doses (n=17)
Age (yrs), mean ( $\pm$ SD)	67.3 (12.2)
Female gender, n (%)	8 (47)
Male gender, n (%)	9 (53)
<b>Vaccination type/schedule</b>	
mRNA-1273, n (%)	3 (17.6)
BNT162b2, n (%)	14 (82.4)
Mean interval between 2nd and 3rd vaccination (days $\pm$ SD)	139 $\pm$ 21
Median interval between 2nd and 3 <sup>rd</sup> vaccination (days)	139 (IQR 123-156)
Mean interval between 3rd vaccine dose and sampling (days $\pm$ SD)	15 $\pm$ 2.4
Median interval between 3rd vaccine dose and sampling (days)	14 (IQR 14-17.5)
<b>RA disease characteristics</b>	
ACPA $\pm$ RF positivity, n (%)	12/17 (71)
RA disease duration (yrs $\pm$ SD)	13 $\pm$ 10
<b>DMARD therapy</b>	
Monotherapy of csDMARDs, n (%)	1/17 (5.9)
bDMARDs, n (%)	8/17 (47.1)
Monotherapy of bDMARDs, n (%)	3/8 (37.5)
JAK inhibitors, n (%)	8/17 (47.1)
Monotherapy of JAK inhibitors, n (%)	3/8 (37.5)
Prednisone, n (%)	6/17 (35.3)
Mean daily dose prednisone (mg $\pm$ SD)	5 $\pm$ 2.2
Median daily dose prednisone (mg)	5 (IQR 5-5)

ACPA: anti-citrullinated protein autoantibodies. RF: rheumatoid factor. DMARD: Disease-modifying antirheumatic drugs. Cs: conventional synthetic. b: biologic. JAK: Janus kinase.